Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louise Emmett

Showing results (1-10 of 187) with videos related to

Pageof 19
Sort By:
European Urology Focus|May 23, 2026
Radioligand Therapy Hormone Combinations and the ENZA-p TrialLouise Emmett
Clinical Advances in Hematology & Oncology : H&O|October 6, 2025
Targeting prostate-specific membrane antigen in prostate cancerLouise Emmett
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 2, 2025
SPECT Deserves RESPECT: The Potential of SPECT/CT to Optimize Patient Outcomes with Theranostics TherapyLouise Emmett
Seminars in Oncology Nursing|July 18, 2020
Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate CancerLouise Emmett
Current Opinion in Urology|August 1, 2020
Clinical impact of PET imaging in prostate cancer managementLouise Emmett, George Hruby
European Urology|July 30, 2023
Prostate-specific Membrane Antigen Imaging Remains True to its Name in Primary Staging of Prostate Cancer: The Time To Characterize its Impact on Clinical Outcomes Is NowFrédéric Pouliot, Louise Emmett
European Urology|January 30, 2026
Reply to Armando Stabile, Giorgio Gandaglia, Arturo Chiti, and Francesco Montorsi's Letter to the Editor re: Ken Herrmann, Jochen Walz, Steven MacLennan, et al. SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.08.005Ken Herrmann, Louise Emmett,
European Urology|July 29, 2019
Tumour Heterogeneity and Resistance to Therapy in Prostate Cancer: A Fundamental Limitation of Prostate-specific Membrane Antigen Theranostics or a Key Strength?Michael S Hofman, Louise Emmett
The Journal of Urology|November 10, 2021
Editorial CommentMatthew J Roberts, Louise Emmett
The Journal of Urology|October 22, 2019
Editorial CommentLouise Emmett, Michael S Hofman
Pageof 19

Showing results (1-10 of 187) with videos related to

Sort By:
Pageof 19
European Urology Focus|May 23, 2026
Radioligand Therapy Hormone Combinations and the ENZA-p TrialLouise Emmett
Clinical Advances in Hematology & Oncology : H&O|October 6, 2025
Targeting prostate-specific membrane antigen in prostate cancerLouise Emmett
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 2, 2025
SPECT Deserves RESPECT: The Potential of SPECT/CT to Optimize Patient Outcomes with Theranostics TherapyLouise Emmett
Seminars in Oncology Nursing|July 18, 2020
Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate CancerLouise Emmett
Current Opinion in Urology|August 1, 2020
Clinical impact of PET imaging in prostate cancer managementLouise Emmett, George Hruby
European Urology|July 30, 2023
Prostate-specific Membrane Antigen Imaging Remains True to its Name in Primary Staging of Prostate Cancer: The Time To Characterize its Impact on Clinical Outcomes Is NowFrédéric Pouliot, Louise Emmett
European Urology|January 30, 2026
Reply to Armando Stabile, Giorgio Gandaglia, Arturo Chiti, and Francesco Montorsi's Letter to the Editor re: Ken Herrmann, Jochen Walz, Steven MacLennan, et al. SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.08.005Ken Herrmann, Louise Emmett,
European Urology|July 29, 2019
Tumour Heterogeneity and Resistance to Therapy in Prostate Cancer: A Fundamental Limitation of Prostate-specific Membrane Antigen Theranostics or a Key Strength?Michael S Hofman, Louise Emmett
The Journal of Urology|November 10, 2021
Editorial CommentMatthew J Roberts, Louise Emmett
The Journal of Urology|October 22, 2019
Editorial CommentLouise Emmett, Michael S Hofman
Pageof 19